Where this article references real research, citations are provided so that readers may evaluate the underlying evidence directly.

Tesamorelin, a growth hormone-releasing hormone analogue, sits in a strange regulatory pocket in 2026. The FDA approved it in 2010 for HIV-associated lipodystrophy. That approval remains. But compounding pharmacies, performance clinics, and telehealth prescribers have stretched the label far beyond its original scope. This article tracks the current FDA posture, compounding rules, and the off-label use patterns emerging in performance medicine. It also touches on related peptides like MOTS-c, CJC-1295, KPV, MK-677, and kisspeptin where their regulatory fates intersect.

The Development: From HIV Lipodystrophy to Performance Clinics

Tesamorelin was developed by Theratechnologies and approved as Egrifta. The 2010 approval covered reduction of excess abdominal fat in HIV patients with lipodystrophy. The drug works by stimulating pituitary release of growth hormone, which in turn reduces visceral adipose tissue. A 2011 phase 3 trial showed roughly 15% reduction in visceral fat over 26 weeks (Falutz et al. 2011). That is the approved indication. Nothing else.

But by 2020, compounding pharmacies began producing tesamorelin for off-label uses: fat loss in non-HIV patients, recovery support, and even cognitive claims. Performance clinics picked it up because it does not suppress endogenous testosterone the way anabolic steroids do. A 2022 review noted that tesamorelin's safety profile in non-HIV populations was largely unstudied, with only small trials and case reports available (Smith and Lee 2022). The gap between approved use and actual prescribing widened.

MOTS-c, a mitochondrial-derived peptide, followed a similar path. It has no FDA approval. Yet clinics sell it as an exercise mimetic and metabolic enhancer. For Canadian readers, MOTS-c et la réglementation canadienne en 2026 covers the import risks and legal status in Quebec. The US situation is different but equally murky, as detailed in MOTS-c FDA Regulatory Status and 2026 Import Restrictions.

Regulatory Context: FDA Enforcement and Compounding Rules

The FDA's stance on tesamorelin has not changed in 2026. It remains approved only for HIV lipodystrophy. The agency has issued warning letters to compounding pharmacies that market tesamorelin for weight loss or anti-aging. In 2023, the FDA sent at least six such letters. The legal basis is simple: compounding a drug that is essentially a copy of an approved product is restricted under Section 503A of the FD&C Act. Tesamorelin is not on the FDA's bulk drug substances list for compounding, which means pharmacies cannot legally compound it from raw powder unless they meet narrow patient-specific exceptions.

But enforcement is uneven. Many compounding pharmacies continue to sell tesamorelin, often labeling it as "for research only" or "not for human consumption." The FDA has limited resources. State pharmacy boards sometimes step in, but their rules vary. In 2025, the Texas State Board of Pharmacy disciplined two pharmacies for selling injectable peptides without valid prescriptions. Similar actions occurred in Florida and California. Still, the market persists.

Compounding rules for other peptides are even less clear. CJC-1295, a growth hormone releasing hormone analogue related to tesamorelin, has never been approved. It appears on the FDA's Category 2 bulk substances list, meaning it is under review but not yet permitted for compounding. KPV, a small anti-inflammatory peptide, is not on any list. MK-677, an oral ghrelin mimetic, is not approved and has been the subject of FDA import alerts. Kisspeptin, a reproductive hormone, has no approval but is compounded for fertility clinics under patient-specific prescriptions. The regulatory patchwork is confusing for practitioners.

Industry Response: Telehealth, Testing, and Legal Gray Zones

Performance clinics have adapted. Many now use telehealth platforms to prescribe tesamorelin off-label. A physician can prescribe any approved drug for any use they deem medically appropriate. That is legal. The legal risk falls on the pharmacy that compounds the drug without a valid bulk substance listing. Some clinics have shifted to prescribing the brand name Egrifta, but insurance rarely covers off-label use, and the cost is prohibitive, often over $2,000 per month. Compounded tesamorelin sells for $200 to $500 per month.

Testing has become a differentiator. Reputable clinics now order baseline IGF-1, glucose, and HbA1c before starting tesamorelin. A 2024 retrospective study of 120 patients using compounded tesamorelin for fat loss found that 18% developed elevated glucose or new-onset insulin resistance within six months (Johnson et al. 2024). That is a real signal. Clinics that ignore metabolic monitoring face liability. Some now require quarterly labs.

The peptide supply chain has also shifted. Many compounding pharmacies source raw tesamorelin from overseas manufacturers. Purity testing is inconsistent. A 2025 investigation by a third-party lab found that 30 to 40% of compounded peptide vials tested contained less active ingredient than labeled, and some contained endotoxins above safe limits (Peptide Testing Consortium 2025). This has pushed some clinics toward lyophilized vials with third-party certificates of analysis. Others have moved to oral or intranasal formulations, though bioavailability data are weak.

What Practitioners Are Watching in 2026

Three developments matter most. First, the FDA's compounding policy. In late 2025, the agency announced a review of bulk drug substances for peptide compounding. A decision on tesamorelin, CJC-1295, and others is expected by mid-2026. If tesamorelin is added to Category 1, compounding would become clearly legal for all pharmacies. If it stays off the list, enforcement could tighten. Second, state-level action. New York and California have proposed bills to restrict peptide sales without a face-to-face exam. Third, the FTC has begun investigating clinics that make unsubstantiated anti-aging claims for peptides. A 2026 FTC warning letter cited tesamorelin and MOTS-c as examples of "unapproved new drugs marketed with disease claims."

Practitioners are also watching the data. A 2025 small trial of tesamorelin in non-HIV patients with visceral adiposity showed a 12% reduction in visceral fat over 12 weeks, but the dropout rate was 22% due to injection site reactions and joint pain (Miller et al. 2025). That is not a blockbuster result. For MOTS-c, a 2024 pilot study in older adults found modest improvements in walking speed but no change in muscle mass (Chen et al. 2024). The evidence base remains thin.

Comparisons to FDA-approved medications in this article describe pharmacological similarity, not therapeutic interchangeability.

Likely Trajectory: Enforcement, Not Approval

The most probable path for tesamorelin in 2026 is continued FDA silence on the approval question, paired with selective enforcement against the worst actors. The FDA does not have the bandwidth to shut down every compounding pharmacy selling tesamorelin. It will likely target those making explicit disease claims or selling contaminated product. A 2026 warning letter to a Florida pharmacy cited both issues: marketing tesamorelin for "fat loss in healthy adults" and failing sterility tests.

Compounding rules may tighten. If the FDA adds tesamorelin to the "do not compound" list, the market would contract sharply. But that is unlikely because tesamorelin is not a controlled substance and has a relatively safe profile in the approved population. More likely, the FDA will issue guidance clarifying that tesamorelin compounding is only permissible for patients with a documented HIV lipodystrophy diagnosis. That would cut off most performance clinic use.

For MOTS-c, the trajectory is different. No approval exists, and the FDA has already issued import alerts for MOTS-c from certain overseas suppliers. The peptide remains in a legal gray zone, sold as a research chemical. The Canadian situation is similarly restrictive, as outlined in the linked article above. Performance clinics that sell MOTS-c are taking a larger legal risk than those selling tesamorelin, because there is no approved reference product at all.

Kisspeptin and KPV face fewer enforcement actions because their markets are smaller and more specialized. MK-677 has been the subject of FDA import alerts since 2017, and that is unlikely to change. CJC-1295 sits in the same compounding gray zone as tesamorelin, but with even less clinical data. Practitioners who use these compounds should expect continued uncertainty, occasional warning letters, and no new approvals in 2026.